Genistein Sensitizes Inhibitory Effect of Tamoxifen on the Growth of Estrogen Receptor-positive and HER2-overexpressing Human Breast Cancer Cells

Overview

Journal Mol Carcinog

Specialties Molecular Biology
Oncology

Date 2007 Feb 14

PMID 17295235

Citations 46

Authors

Zhiming Mai

George L Blackburn

Jin-Rong Zhou

Affiliations

Soon will be listed here.

Abstract

Although tamoxifen (TAM) is used for the front-line treatment and prevention of estrogen receptor-positive (ER+) breast tumors, nearly 40% of estrogen-dependent breast tumors do not respond to TAM treatment. Moreover, the positive response is usually of short duration, and most tumors eventually develop TAM-resistance. Overexpression of HER2 gene is associated with TAM-resistance of breast tumor, and suppression of HER2 expression enhances the TAM activity. Soy isoflavone genistein has been shown to have anti-cancer activities and suppress expression of HER2 and ERalpha. The objective of this study was to test the hypothesis that genistein may sensitize the response of ER+ and HER2-overexpressing breast cancer cells to TAM treatment. The combination treatment of TAM and genistein inhibited the growth of ER+/HER2-overexpressing BT-474 human breast cancer cells in a synergistic manner in vitro. Determination of cellular markers indicated that this synergistic inhibitory effect might be contributed in part from combined effects on cell-cycle arrest at G(1) phase and on induction of apoptosis. Further determination of the molecular markers showed that TAM and genistein combination synergistically induced BT-474 cell apoptosis in part by synergistic downregulation of the expression of survivin, one of the apoptotic effectors, and downregulation of EGFR, HER2, and ERalpha expression. Our research may provide a novel approach for the prevention and/or treatment of TAM insensitive/resistant human breast cancer, and warrants further in vivo studies to verify the efficacy of genistein and TAM combination on the growth of ER+/HER2-overexpressing breast tumors and to elucidate the in vivo mechanisms of synergistic actions.

Citing Articles

Mechanism of action of genistein on breast cancer and differential effects of different age stages.

Xiang Z, Ma B, Pei X, Wang W, Gong W Pharm Biol. 2025; 63(1):141-155.

PMID: 39996512 PMC: 11864014. DOI: 10.1080/13880209.2025.2469607.

Dietary isoflavone intake among breast cancer survivors and cancer-free women.

Song S, Moon H, Noh D, Jung S, Lee E, Kim Z Nutr Res Pract. 2025; 19(1):80-95.

PMID: 39959749 PMC: 11821773. DOI: 10.4162/nrp.2025.19.1.80.

Cellular and Molecular Mechanisms Modulated by Genistein in Cancer.

Naponelli V, Piscazzi A, Mangieri D Int J Mol Sci. 2025; 26(3).

PMID: 39940882 PMC: 11818640. DOI: 10.3390/ijms26031114.

Soy Isoflavone Genistein Enhances Tamoxifen Sensitivity in Breast Cancer via microRNA and Glucose Metabolism Modulation.

Shpigel J, Luciano E, Ukandu B, Sauane M, de la Parra C Int J Mol Sci. 2025; 26(2).

PMID: 39859445 PMC: 11765730. DOI: 10.3390/ijms26020733.

Polyphenols as Immunomodulators and Epigenetic Modulators: An Analysis of Their Role in the Treatment and Prevention of Breast Cancer.

Eren E, Das J, Tollefsbol T Nutrients. 2024; 16(23).

PMID: 39683540 PMC: 11644657. DOI: 10.3390/nu16234143.

References

Cobleigh M, Vogel C, Tripathy D, Robert N, Scholl S, Fehrenbacher L . Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999; 17(9):2639-48. DOI: 10.1200/JCO.1999.17.9.2639. View

Markiewicz L, GAREY J, Adlercreutz H, GURPIDE E . In vitro bioassays of non-steroidal phytoestrogens. J Steroid Biochem Mol Biol. 1993; 45(5):399-405. DOI: 10.1016/0960-0760(93)90009-l. View

Kurokawa H, Lenferink A, Simpson J, Pisacane P, Sliwkowski M, Forbes J . Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells. Cancer Res. 2000; 60(20):5887-94. View

Nakayama Y, Sakamoto H, Satoh K, Yamamoto T . Tamoxifen and gonadal steroids inhibit colon cancer growth in association with inhibition of thymidylate synthase, survivin and telomerase expression through estrogen receptor beta mediated system. Cancer Lett. 2000; 161(1):63-71. DOI: 10.1016/s0304-3835(00)00600-5. View

Slamon D, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A . Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001; 344(11):783-92. DOI: 10.1056/NEJM200103153441101. View

Bandala E, Espinosa M, Maldonado V, Melendez-Zajgla J . Inhibitor of apoptosis-1 (IAP-1) expression and apoptosis in non-small-cell lung cancer cells exposed to gemcitabine. Biochem Pharmacol. 2001; 62(1):13-9. DOI: 10.1016/s0006-2952(01)00632-3. View

Kawasaki H, Toyoda M, Shinohara H, Okuda J, Watanabe I, Yamamoto T . Expression of survivin correlates with apoptosis, proliferation, and angiogenesis during human colorectal tumorigenesis. Cancer. 2001; 91(11):2026-32. DOI: 10.1002/1097-0142(20010601)91:11<2026::aid-cncr1228>3.0.co;2-e. View

Chung Y, Sheu M, Yang S, Lin C, Yen S . Resistance to tamoxifen-induced apoptosis is associated with direct interaction between Her2/neu and cell membrane estrogen receptor in breast cancer. Int J Cancer. 2002; 97(3):306-12. DOI: 10.1002/ijc.1614. View

Bao R, Connolly D, Murphy M, Green J, Weinstein J, Pisarcik D . Activation of cancer-specific gene expression by the survivin promoter. J Natl Cancer Inst. 2002; 94(7):522-8. DOI: 10.1093/jnci/94.7.522. View

10.

Suzuki K, Koike H, Matsui H, Ono Y, Hasumi M, Nakazato H . Genistein, a soy isoflavone, induces glutathione peroxidase in the human prostate cancer cell lines LNCaP and PC-3. Int J Cancer. 2002; 99(6):846-52. DOI: 10.1002/ijc.10428. View

11.

Katdare M, Osborne M, Telang N . Soy isoflavone genistein modulates cell cycle progression and induces apoptosis in HER-2/neu oncogene expressing human breast epithelial cells. Int J Oncol. 2002; 21(4):809-15. View

12.

Chen W, Huang M, Tzang C, Yang M, Wong M . Inhibitory actions of genistein in human breast cancer (MCF-7) cells. Biochim Biophys Acta. 2003; 1638(2):187-96. DOI: 10.1016/s0925-4439(03)00082-6. View

13.

Zhou J, Yu L, Mai Z, Blackburn G . Combined inhibition of estrogen-dependent human breast carcinoma by soy and tea bioactive components in mice. Int J Cancer. 2003; 108(1):8-14. PMC: 2706156. DOI: 10.1002/ijc.11549. View

14.

Lichtner R . Estrogen/EGF receptor interactions in breast cancer: rationale for new therapeutic combination strategies. Biomed Pharmacother. 2003; 57(10):447-51. DOI: 10.1016/j.biopha.2003.09.006. View

15.

Argiris A, Wang C, Whalen S, DiGiovanna M . Synergistic interactions between tamoxifen and trastuzumab (Herceptin). Clin Cancer Res. 2004; 10(4):1409-20. DOI: 10.1158/1078-0432.ccr-1060-02. View

16.

Chou T, Talalay P . Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984; 22:27-55. DOI: 10.1016/0065-2571(84)90007-4. View

17.

Slamon D, Clark G, Wong S, Levin W, Ullrich A, McGuire W . Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987; 235(4785):177-82. DOI: 10.1126/science.3798106. View

18.

Markovits J, Linassier C, Fosse P, Couprie J, Pierre J, Jacquemin-Sablon A . Inhibitory effects of the tyrosine kinase inhibitor genistein on mammalian DNA topoisomerase II. Cancer Res. 1989; 49(18):5111-7. View

19.

Muss H . Endocrine therapy for advanced breast cancer: a review. Breast Cancer Res Treat. 1992; 21(1):15-26. DOI: 10.1007/BF01811960. View

20.

Messina M, Persky V, Setchell K, Barnes S . Soy intake and cancer risk: a review of the in vitro and in vivo data. Nutr Cancer. 1994; 21(2):113-31. DOI: 10.1080/01635589409514310. View